Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D207/12—Oxygen or sulfur atoms
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
  • G01N33/6869—Interleukin
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
  • G01N2333/52—Assays involving cytokines
  • G01N2333/525—Tumor necrosis factor [TNF]

Definitions

• Tumor necrosis factor alpha is a cytokine that is released primarily by inflammation and mononuclear phagocytes in response to immunostimulators. TNF- ⁇ is capable of enhancing most cellular processes, such as differentiation, recruitment, proliferation, and proteolytic degradation. At low levels, TNF- ⁇ confers protection against infective agents, tumors, and tissue damage. However, TNF- ⁇ also has a role in many diseases. When administered to mammals such as humans, TNF- ⁇ causes or aggravates inflammation, fever, cardiovascular effects, hemorrhage, coagulation, and acute phase responses similar to those seen during acute infections and shock states.
• Enhanced or unregulated TNF- ⁇ production has been implicated in a number of diseases and medical conditions, for example, cancers, such as solid tumors and blood-born tumors; heart disease, such as congestive heart failure; and viral, genetic, inflammatory, allergic, and autoimmune diseases.
• IAP Inhibitor compounds compounds which inhibit the binding of the Smac protein to IAP (hereinafter "IAP Inhibitor compounds”) as single agents, anti-tumor activity results from the release of a block to a proapoptotic autocrine TNF- ⁇ signaling loop.
• the coordinate consequences of releasing this block are an increase in the production of TNF ⁇ and facilitation of TNF ⁇ -mediated apoptosis.
• Proliferative diseases within the scope of the present invention are those where TNF ⁇ signaling is constitutively on.
• cytokine levels i.e., IL-8
• IL-8 cytokine levels in circulating blood may reflect therapeutic effect of IAP Inhibitor compounds and thus may be used as biomarkers.
• the invention also relates to methods to predict the responsiveness of a patient with a TNF- ⁇ responsive disease to a IAP inhibitor compound.
• this invention relates to predicting a patient's response to an IAP inhibitor compound by measuring TNF- ⁇ levels, possibly pre- and post-treatment.
• the present invention overcomes deficiencies in the use of IAP inhibitor compounds by providing a method to determine which individual with a disease characterized by constitutive TNF- ⁇ signaling will respond to treatment with a IAP inhibitor compound.
• the present invention relates to the use of compounds that inhibit the binding of the Smac protein to IAPs ("IAP inhibitor") for the treatment of diseases characterized by constitutive TNF- ⁇ signaling, and to a method for the manufacture of a medicament for treating diseases characterized by constitutive TNF- ⁇ signaling, and to a method for the treatment of warm-blooded animals, including humans, wherein an IAP inhibitor is administered to a warm-blooded animal suffering diseases characterized by constitutive TNF- ⁇ signaling, especially proliferative diseases effected by cytokine production such as cancer, arthritis, sepsis, cancer associated cachexia, Crohn's disease and other inflammatory disorders.
• IAP inhibitor IAP inhibitor
• Figure 1 shows (a) a correlation between sensitivity to Compound Il and TNF mRNA levels within a panel of tumor cell lines, (b) that tumor cell lines which are sensitive to IAP inhibitor compounds are induced to increase TNF mRNA levels as part of their response.
• Figure 2 shows the increase of TNF ⁇ mRNA correlating to compounds Il and III in SKOV-3 cells in a dose dependent manner.
• this invention provides a method to predict which patients will respond to a IAP inhibitor compound in patients having a disease characterized by constitutive TNF- ⁇ signaling comprising:
• TNF- ⁇ levels in the patient increase upon administration of the IAP inhibitor compound, this is an indication that the compound is working.
• the present invention relates to the use of compounds that inhibit the binding of the Smac protein to IAPs ("IAP inhibitors") to manufacture a medicament for the treatment of diseases characterized by constitutive TNF- ⁇ signaling.
• IAP inhibitors compounds that inhibit the binding of the Smac protein to IAPs
• the present invention also relates to a method to treat diseases characterized by constitutive TNF- ⁇ signaling by administering IAPs inhibitors in combination with TNF- ⁇ , Interferon-alpha or Interferon-gamma or other agents which modulate TNF- ⁇ signaling.
• IAP inhibitors for use in the present invention include compounds of formula I:
• R 1 is H, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl or C 3 -C 10 cycloalkyl, which R 1 may be unsubstituted or substituted;
• R 2 is H, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 3 -C 10 cycloalkyl which R 2 may be unsubstituted or substituted;
• R 3 is H, CF 3 , C 2 F 5 , C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, CH 2 -Z or R 2 and R 3 taken together with the nitrogen atom to which they are attached form a heterocyclic ring, which alkyl, alkenyl, alkynyl or het ring may be unsubstituted or substituted;
• Z is H, OH 1 F, Cl, CH 3 , CH 2 CI, CH 2 F or CH 2 OH;
• R 4 is C O -i O alkyl, C 3 -C 10 cycloalkyl, wherein the C 0-10 alkyl, or cycloalkyl group is unsubstituted or substituted;
• A is het, which may be substituted or unsubstituted
• D is C 1 -C 7 alkylene or C 2 -C 9 alkenylene, C(O) 1 O, NR 7 , S(O)r, C(O)-C 1 -C 10 alkyl, 0-C 1 - C 10 alkyl, S(OJr-C 1 -C 10 alkyl, C (O) C 0 -C 10 arylalkyl OC 0 -C 10 arylalkyl, or S(O)r C 0 -C 10 arylalkyl, which alkyl and aryl groups may be unsubstituted or substituted; r is O, 1 , or 2;
• a 1 is a substituted aryl or unsubstituted or substituted het which substituents on aryl and het are halo, lower alkoxy, NR 5 R 6 , CN, NO 2 or SR 5 ; each Q is independently H, C 1 -C 10 alkyl, C 1 -C 10 alkoxy, aryl C 1 -C 10 alkoxy, OH, 0-C 1 - do-alkyl, (CH 2 ) o - ⁇ -C 3 -C 7 cycloalkyl, aryl, aryl C 1 -C 10 alkyl, 0-(CH 2 ) o _ 3 aryl, (CH 2 ) r ⁇ het, het, O-(CH 2 ) 1-6 het, -OR 11 , C(O)R 11 , -C(O)N(R 11 )(R 12 ), N(R 11 )(R 12 J 1 SR 11 , S(O
• R 11 and R 12 are independently H, C 1 -C 10 alkyl, (CH 2 ) M -C 3 -C 7 cycloalkyl, (CH 2 ) o- ⁇ - (CH) o-1 (aryl) 1-2 ,C(0)-C 1 -C 1o alkyl, -CfOMCHzKe-Crdcycloalkyl, -C(0)-0-(CH 2 ) o ⁇ -aryl, -C(O)- (CH 2 ) o-6 -0-fluorenyl, C(0)-NH-(CH 2 ) o-6 -aryl, C(O)-(CH 2 ) 0 .
• R 5 , R 6 and R 7 are independently hydrogen, lower alkyl, aryl, aryl lower alkyl, cycloalkyl, or cycloalkyl lower alkyl, and wherein the substituents on R 1 , R 2 , R3, R 4 , Q, and A and A 1 groups are independently halo, hydroxy, lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, lower alkoxy, aryl, aryl lower alkyl, amino, amino lower alkyl, diloweralkylamino, lower alkanoyl, amino lower alkoxy, nitro, cyano, cyano lower alkyl, carboxy, lower carbalkoxy, lower alkanoyl, aryloyl, lower arylalkanoyl, carbamoyl, N-mono- or N,N-dilower alkyl carbamoyl, lower alkyl carbamic acid ester, amidino, gu
• R 9 , R 10 , and R 13 are independently hydrogen, lower alkyl, halogen substituted lower alkyl, aryl, aryl lower alkyl, halogen substituted aryl, halogen substituted aryl lower alkyl.
• R 9 , R 10 , and R 13 are independently hydrogen, lower alkyl, halogen substituted lower alkyl, aryl, aryl lower alkyl, halogen substituted aryl, halogen substituted aryl lower alkyl.
• the preferred compounds are selected from the group consisting of (S)-N-((S)-1- Cyclohexyl-2- ⁇ (S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl ⁇ -2-oxo-ethyl)-2- methylamino-propionamide (Compound II); (S)-N-[(S)-Cyclohexyl-(ethyl- ⁇ (S)-1-[5-(4-fluoro- benzoyl)-pyridin-3-yl]-propyl ⁇ carbamoyl)-methyl]-2-methylamino-propionamide (Compound III); (S)-N-((S)-1-Cyclohexyl-2- ⁇ (S)-2-[5-(4-fluoro-phenoxy)-pyridin-3-yl]-pyrrolidin-1-yl ⁇ -2- oxo-ethyl
• IAP inhibitors examples include compounds disclosed in WO 05/097791 published on October 20, 2005, which is hereby incorporated into the present application by reference.
• a preferred compound within the scope of formula (I) is ⁇ /-[1-cyclohexyl-2-oxo-2- ( ⁇ -phenethyl-octahydro-pyrrolo ⁇ .S-clpyridin-i-yl-ethyll ⁇ -methylamino-propionamide, hereinafter compound II.
• IAP inhibitors include compounds disclosed in WO 04/005284, PCT/US2006/013984, PCT/US2006/021850 all of which are hereby incorporated into the present application by reference.
• IAP inhibitor compounds for use in the present invention include those disclosed in WO 06/069063, WO 05/069888, US2006/0014700, WO 04/007529, US2006/0025347, WO 06/010118, WO 05/069894, WO 06/017295, WO 04/007529, WO 05/094818.
• treatment or “therapy” (especially of tyrosine protein kinase dependent diseases or disorders) refer to the prophylactic or preferably therapeutic (including but not limited to palliative, curing, symptom-alleviating, symptom-reducing, kinase-regulating and/or kinase-inhibiting) treatment of said diseases, especially of the diseases mentioned below.
• a warm-blooded animal (or patient) is preferably a mammal, especially a human.
• this includes any one or more of the following embodiments of the invention, respectively (if not stated otherwise): the use in the treatment of a disease (especially diseases mediated or exacerbated by excessive TNF- ⁇ or characterized by constitutive TNF- ⁇ signaling), the use for the manufacture of pharmaceutical compositions for use in the treatment of diseases mediated or exacerbated by excessive TNF- ⁇ or characterized by constitutive TNF- ⁇ signaling, methods of use of one or more IAP inhibitors in the treatment of a disease mediated or exacerbated by excessive TNf- ⁇ or characterized by constitutive TNF- ⁇ signaling, pharmaceutical preparations comprising one or more IAP inhibitors for the treatment of said disease mediated or exacerbated by excessive TNF- ⁇ or characterized by constitutive TNF- ⁇ signaling, and one or more IAP inhibitors in the treatment of said disease mediated or exacerbated by excessive TNF
• an IAP inhibitor in the therapy (including prophylaxis) of a proliferative disorder (especially which is characterized by constitutive TNF- ⁇ signaling) selected from tumor or cancer diseases, especially against preferably a benign or especially malignant tumor or cancer disease, more preferably solid tumors, e.g. carcinoma of the brain, kidney, liver, adrenal gland, bladder, breast, stomach (especially gastric tumors), ovaries, colon, rectum, prostate, pancreas, lung (e.g.
• small or large cell lung carcinomas vagina, thyroid, sarcoma, glioblastomas, multiple myeloma (MM) or gastrointestinal cancer, especially colon carcinoma or colorectal adenoma, or a tumor of the neck and head, e.g. squameous carcinoma of the head and neck, including neoplasias, especially of epithelial character, e.g. in the case of mammary carcinoma; an epidermal hyperproliferation (other than cancer), especially psoriasis; prostate hyperplasia; or a leukemia, especially acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).
• AML acute myeloid leukemia
• CML chronic myeloid leukemia
• the precise dosage of an IAP inhibitor compound to be employed depends upon several factors including the host, the nature and the severity of the condition being treated, the mode of administration.
• the IAP inhibitor compound can be administered by any route including orally, parenterally, e.g., intraperitoneal ⁇ , intravenously, intramuscularly, subcutaneously, intratumorally, or rectally, or enterally.
• the IAP inhibitor compound is administered orally, preferably at a daily dosage of 1-300 mg/kg body weight or, for most larger primates, a daily dosage of 50-5000, preferably 500-3000 mg.
• a preferred oral daily dosage is 1-75 mg/kg body weight or, for most larger primates, a daily dosage of 10-2000 mg, administered as a single dose or divided into multiple doses, such as twice daily dosing.
• a small dose is administered initially and the dosage is gradually increased until the optimal dosage for the host under treatment is determined.
• the upper limit of dosage is that imposed by side effects and can be determined by trial for the host being treated.
• Dosage regimens must be titrated to the particular indication, the age, weight, and general physical condition of the patient, and the response desired but generally doses will be from about 10 to about 500 mg/day as needed in single or multiple daily administration.
• an initial treatment regimen can be copied from that known to be effective in interfering with TNF- ⁇ activity for other TNF- ⁇ mediated disease states by the compounds of the present invention.
• Treated individuals will be regularly checked for T cell numbers and T4/T8 ratios and/or measures of viremia such as levels of reverse transcriptase or viral proteins, and/or for progression of cytokine-mediated disease associated problems such as cachexia or muscle degeneration. If no effect is soon following the normal treatment regimen, then the amount of cytokine activity interfering agent administered is increased; e.g., by fifty percent a week.
• IAP inhibitor compounds may be combined with one or more pharmaceutically acceptable carriers and, optionally, one or more other conventional pharmaceutical adjuvants and administered enterally, e.g. orally, in the form of tablets, capsules, caplets, etc. or parenterally, e.g., intraperitoneally or intravenously, in the form of sterile injectable solutions or suspensions.
• enteral and parenteral compositions may be prepared by conventional means.
• Production of TNF- ⁇ with an IAP inhibitor compound can be conveniently assayed using anti-TNF- ⁇ antibodies. For example, plates (Nunc Immunoplates, Roskilde, DK) are treated with 5 ⁇ g/mL of purified rabbit anti- TNF- ⁇ antibodies at 4°C for 12 to 14 hours.
• the plates then are blocked for 2 hours at 25°C with PBS/0.05% Tween containing 5 mg/mL BSA. After washing, 100 ⁇ L of unknowns as well as controls are applied and the plates incubated at 4°C for 12 to 14. hours. The plates are washed and assayed with a conjugate of peroxidase (horseradish) and mouse anti-TNF- ⁇ monoclonal antibodies, and the color developed with o-phenylenediamine in phosphate-citrate buffer containing 0.012% hydrogen peroxide and read at 492 nm.
• peroxidase horseradish
• FIG. 1 shows that sensitive cell lines (72 hour IC50 ⁇ 1 uM) express higher baseline levels of TNF mRNA and respond to Compound Il treatment by increasing expression of TNF mRNA. Implicit in these findings is that TNF levels may be used to predict sensitivity to a Smac Mimetic compound and that assessment of rising TNF levels may have potential as a strategy for monitoring a therapeutic response.
• FIG. 2 shows how compounds Il and III induce TNF ⁇ mRNA in SKOV-3 cells in a dose dependent manner.
• TNF ⁇ induction required proteosome activity since it is inhibited by MG132 (Pl).
• TNF ⁇ induction does not require Caspase activity (is not blocked by ZVAD) but does require autocrine TNF ⁇ signaling since it is blocked with soluble TNF ⁇ receptor (STR).
• the graph depicting TNF induction by compound Il includes nine bars correlating to the fold increase of TNF relative to untreated cells. Reading from left to right, the first bar represents untreated cells (app. 0-1 fold). The second bar represents 1000 nM of compound
• the third bar represents 100 nM of compound Il (app. 50 fold increase).
• the fourth bar represents 1000 nM of compound Il + Pl (app. 25-30 fold increase).
• the fifth bar represents 100 nM of compound Il + Pl (app. 15-20 fold increase).
• the sixth bar represents 1000 nM of compound Il + ZVAD (app. 125-130 fold increase).
• the seventh bar represents 100 nM compound Il + ZVAD (app. 95-100 fold increase).
• the eighth bar represents 1000 nM compound Il + sTNFR (app. 0-5 fold increase).
• the ninth bar represents 100 nm compound Il + sTNFR (app. 0-1).
• the graph depicting TNF induction by compound III includes nine bars correlating to the fold increase of TNF relative to untreated cells. Reading from left to right, the first bar represents untreated cells (app. 0-1 fold). The second bar represents 1000 nM of compound
• the third bar represents 100 nM of compound III (app. 85- 95 fold increase).
• the fourth bar represents 1000 nM of compound III + Pl (app. 30-40 fold increase).
• the fifth bar represents 100 nM of compound III + Pl (app. 15-20 fold increase).
• the sixth bar represents 1000 nM of compound III + ZVAD (app. 75-80 fold increase).
• the seventh bar represents 100 nM compound III + ZVAD (app. 85-95 fold increase).
• the eighth bar represents 1000 nM compound III + sTNFR (app. 0-1 fold increase).
• the ninth bar represents 100 nm compound III + sTNFR (app. 0-3 fold increase).

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Molecular Biology (AREA)
• Urology & Nephrology (AREA)
• Organic Chemistry (AREA)
• Hematology (AREA)
• Biomedical Technology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Cell Biology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biotechnology (AREA)
• Pathology (AREA)
• General Physics & Mathematics (AREA)
• Biochemistry (AREA)
• Microbiology (AREA)
• Analytical Chemistry (AREA)
• Food Science & Technology (AREA)
• Physics & Mathematics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Oncology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Communicable Diseases (AREA)
• Rheumatology (AREA)
• Virology (AREA)
• Pain & Pain Management (AREA)
• Vascular Medicine (AREA)
• Pulmonology (AREA)
• Physical Education & Sports Medicine (AREA)

Priority Applications (7)

Applications Claiming Priority (4)

Publications (2)

Family

ID=39364966

Family Applications (1)

Country Status (10)

Cited By (16)

Families Citing this family (5)

Family Cites Families (3)

• 2007
  • 2007-10-17 KR KR1020097009957A patent/KR20090082221A/ko not_active Withdrawn
  • 2007-10-17 US US12/446,430 patent/US20100316573A1/en not_active Abandoned
  • 2007-10-17 CA CA002665838A patent/CA2665838A1/en not_active Abandoned
  • 2007-10-17 BR BRPI0717411-0A2A patent/BRPI0717411A2/pt not_active IP Right Cessation
  • 2007-10-17 RU RU2009118487/15A patent/RU2009118487A/ru not_active Application Discontinuation
  • 2007-10-17 JP JP2009533355A patent/JP2010507096A/ja active Pending
  • 2007-10-17 AU AU2007318220A patent/AU2007318220A1/en not_active Abandoned
  • 2007-10-17 WO PCT/US2007/022125 patent/WO2008057172A2/en not_active Ceased
  • 2007-10-17 MX MX2009004061A patent/MX2009004061A/es not_active Application Discontinuation
  • 2007-10-17 EP EP07867238A patent/EP2076778A2/en not_active Withdrawn

Also Published As

Similar Documents

Legal Events